Fundraising FoxSolaris Endovascular
Dallas, US · Founded 2024
Find your way into Solaris Endovascular
Sign up to see every warm intro you have to Solaris Endovascular
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Solaris Endovascular team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Solaris Endovascular develops covered stent grafts and drug-eluting technology for treating dialysis access and peripheral artery disease (PAD) in patients with end-stage kidney disease. Its electrospinning PTFE covered stent grafts target vascular care for hemodialysis access and PAD, serving physicians and distributors.
Founders & leadership
RW
Randolph W. HubbellNamed on SEC filing
AM
Alexander Marra MoreiraNamed on SEC filing
MD
Melchiades de Cunha NetoNamed on SEC filing
MC
Marco CostaChief Scientific & Medical Officer
DS
David StackNamed on SEC filing
MH
Matthew HeadNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$5M disclosed across 1 round · 2025
▶$5MraisedOct 2026 · 45 investors · BiotechnologyRule 506(b)
▶$5MraisedOct 2026 · 45 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Randolph W. HubbellExecutive Officer, Director
- Alexander Marra MoreiraDirector
- Melchiades de Cunha NetoDirector
- Marco CostaDirector
- David StackDirector
- Matthew HeadExecutive Officer
- Offering amount
- $10M
- Amount sold
- $5M
- Minimum investment
- $2.5K
- First sale
- Sep 2025
- Incorporated
- Corporation, Delaware, 2024
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Solaris Endovascular do?
- Solaris Endovascular develops covered stent grafts and drug-eluting technology for treating dialysis access and peripheral artery disease (PAD) in patients with end-stage kidney disease. Its electrospinning PTFE covered stent grafts target vascular care for hemodialysis access and PAD, serving physicians and distributors.
- How much funding has Solaris Endovascular raised?
- Solaris Endovascular has disclosed $5M raised across 1 round.
- Where is Solaris Endovascular headquartered?
- Solaris Endovascular is headquartered in Dallas, US.